Zu den Inhalten springen


The interdisciplinary molecular tumor board (MTB) of the medical center of the university of Freiburg takes a close look at therapeutical options for cancer patients with rare diseases and/or after having exhausted all standard therapy options. Our task is to analyze Next Generation Sequencing (NGS) data of the patients (panels, whole exome sequencing, RNA sequencing, methylome), present and discuss the results and therapeutical options within the interdisciplinary team in the MTB sessions.